2023-12-02T23:05:29+03:00[Europe/Moscow] en true <p>aging, environmental toxins/toxic substances, antipsychotics, VMAT inhibitors</p>, <p>caucasian/hispanic males</p>, <p>rasagiline </p>, <p>consider anticholinergic or carbidopa/levodopa</p>, <p>carbidopa/levodopa </p>, <p>dopamine agonist or carbidopa/levodopa</p>, <p>dopamine agonist; physical therapy</p>, <p>carbidopa/levodopa; physical therapy </p>, <p>b</p>, <p>c</p>, <p>a</p>, <p>c</p>, <p>a</p>, <p>b,e</p>, <p>d</p>, <p>c</p>, <p>b</p>, <p>b</p>, <p>a</p>, <p>a,b</p>, <p>postural instability, gait difficulties, older age</p>, <p>slower; benign </p> flashcards
Parkinson's Therapeutics

Parkinson's Therapeutics

  • aging, environmental toxins/toxic substances, antipsychotics, VMAT inhibitors

    What are the suspected causes of PD? (4)

  • caucasian/hispanic males

    Who is Parkinson's most common in?

  • rasagiline

    How is a patient with no significant impairment treated?

  • consider anticholinergic or carbidopa/levodopa

    How do we treat a patient who is less than 65 yo with a tremor? (2)

  • carbidopa/levodopa

    How do we treat a patient who is >=65 yo with a tremor or bradykinesia/rigidity?

  • dopamine agonist or carbidopa/levodopa

    How is a patient who is less than 65 with bradykinesia/rigidity treated? (2)

  • dopamine agonist; physical therapy

    How do we treat a patient who is less than 65 and has postural

    instability/gait impairment? (2)

  • carbidopa/levodopa; physical therapy

    How is a patient >=65 yo and has postural instability/gait impairment treated? (2)

  • b

    Which is considered the Gold Standard for assessing PD disease

    progression/ treatment response?

    a) Montreal Cognitive Assessment (MoCA)

    b) Unified Parkinson's Disease Rating Scale (UPDRS)

    c) Modified Hoehn & Yahr Scale

  • c

    Which is a 5-stage clinician-rated scale?

    a) Montreal Cognitive Assessment (MoCA)

    b) Unified Parkinson's Disease Rating Scale (UPDRS)

    c) Modified Hoehn & Yahr Scale

  • a

    Which is an assessment of cognitive abilities?

    a) Montreal Cognitive Assessment (MoCA)

    b) Unified Parkinson's Disease Rating Scale (UPDRS)

    c) Modified Hoehn & Yahr Scale

  • c

    Which is an additive to Sinemet and used to treat off periods?

    a) carbidopa/levodopa

    b) MOB-inhibitors

    c) Adenosine A2A antagonist

    d) Apomorphine

    e) dopamine agonist

  • a

    Which is the first choice for managing motor symptoms?

    a) carbidopa/levodopa

    b) MOB-inhibitors

    c) Adenosine A2A antagonist

    d) Apomorphine

    e) dopamine agonist

  • b,e

    Which can be used as a monotherapy in the treatment of early PD with

    minor motor symptoms?

    a) carbidopa/levodopa

    b) MOB-inhibitors

    c) Adenosine A2A antagonist

    d) Apomorphine

    e) dopamine agonist

  • d

    Which is used for severe freezing episodes?

    a) carbidopa/levodopa

    b) MOB-inhibitors

    c) Adenosine A2A antagonist

    d) Apomorphine

    e) dopamine agonist

  • c

    Which medications can NEVER be used as monotherapies?

    a) anticholinergics

    b) amantadine

    c) COMT inhibitors

  • b

    Which improves "on-time" effects?

    a) carbidopa/levodopa

    b) MOB-inhibitors

    c) Adenosine A2A antagonist

    d) Apomorphine

    e) dopamine agonist

  • b

    Which is used to treat dyskinesia associated with Sinemet use?

    a) anticholinergics

    b) amantadine

    c) COMT inhibitors

  • a

    Which is primarily used to treat tremors?

    a) anticholinergics

    b) amantadine

    c) COMT inhibitors

  • a,b

    Which are used in patients in patients less than 65?

    a) anticholinergics

    b) amantadine

    c) COMT inhibitors

  • postural instability, gait difficulties, older age

    Which patients tend to have a poorer prognosis, which symptoms? (3)

  • slower; benign

    Patients who primarily suffer from tremor will have a ______ progression and more ________ course.